ADJUVANT COMPARISON AND CHARACTERIZATION

佐剂比较和表征（ACC）计划的目标是支持佐剂与临床相关疫苗/抗原平台的并行比较，并建立佐剂的全身和组织特异性免疫学特征（“免疫指纹”），这些佐剂通过不同机制发挥作用，并具有针对给定抗原和/或疾病靶标的潜力。通过ACC计划支持的承包商将有望：1）相互合作，包括使用标准化方案或终点检测; 2）在NIAID的指导下筛选其他佐剂; 3）分享积极和消极的结果，以帮助指导计划内和更广泛的科学界的基础研究和疫苗开发活动。此外，ACC支持的研究产生的数据将公开提供，从而能够合理选择佐剂，并在未来开发更有效的传染病疫苗和/或治疗过敏性或自身免疫性疾病的新疫苗。

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms and have potential for a given antigen and/or disease target. Contractors supported through the ACC program will be expected to: 1) collaborate with each other, including using standardized protocols or endpoint assays; 2) screen additional adjuvants at the direction of NIAID; and 3) share both positive and negative results in order to help guide basic research and vaccine development activities within the program and across the broader scientific community. In addition, data generated from ACC-supported studies will be made publicly available, enabling the rational selection of adjuvants and the future development of more effective vaccines against infectious diseases, and/or new vaccines to treat allergic or autoimmune diseases.